Weekly Digest - October 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - October 2025
08 October 2025: Lisata Therapeutics and Catalent announce global antibody-drug conjugate (ADC) license agreement
- Catalent has obtained global rights from Lisata Therapeutics to use certepetide (iRGD peptide) and its analogs as SMARTag ADC payloads for developing therapies targeting difficult-to-treat diseases
- The agreement allows Catalent to develop, commercialize, and partner on bioconjugate products using certepetide worldwide, with Lisata eligible for over $10 million in milestones and future revenue sharing
- Certepetide is an internalizing RGD cyclic peptide designed to enhance tumor targeting, penetration, and therapeutic efficacy when combined with anti-cancer agents
- Preclinical studies by Catalent demonstrated proof-of-concept that incorporating iRGD peptides into SMARTag ADCs improves efficacy and pharmacokinetics
- Data supporting this approach will be presented at the World ADC conference in San Diego, reinforcing both companies’ belief in certepetide’s potential as a novel ADC payload class
